After rejecting it twice, the FDA has finally approved a new drug for lowering the risk of hearing loss among children being treated for cancer with chemotherapy.
Pedmark, as Fennec Pharma calls its drug, is a formulation of sodium thiosulfate. Given that ototoxicity is a major dose-limiting side effect of…
Click here to view original post
